A LinkedIn post from Orbis Medicines highlights growing momentum in oral biologics, referencing an interview between CEO Morten Graugaard and Pharmaceutical Executive. The discussion centers on Johnson & Johnson’s recent FDA approval of Icotyde, an oral macrocycle IL-23 receptor antagonist, as an indicator that oral biologics are moving toward clinical and commercial viability.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
According to the post, the conversation examines remaining hurdles such as improving bioavailability and achieving scalable manufacturing, while positioning oral therapies as competitors to established injectable treatments. The post also points to Orbis’s nGen platform, which is described as enabling programmable, data-driven discovery of orally bioavailable macrocycles, suggesting a technology-focused approach that could enhance the company’s role in next-generation drug development.
For investors, the emphasis on Icotyde’s approval and oral macrocycles may signal an expanding addressable market for small-molecule-like biologics targeting complex pathways. If Orbis’s platform can translate into differentiated assets or attractive partnerships, it could enhance the firm’s strategic value in the biopharma ecosystem, particularly among larger companies seeking capabilities in oral biologic modalities.